Accessibility Menu
Yield10 Bioscience logo

Yield10 Bioscience(OTC) YTEN

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2006)-100%
5 Year-100%
1 Year+0%
1 Month+9,900%
N/A
Yield10 Bioscience last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-24
Yield10 Bioscience stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-07
1 month+9,900%USD 0.002026-07-16
3 month+0%USD 0.002026-05-22
Year to date+9,900%USD 0.002025-12-31
1 year+0%USD 0.002025-08-22
3 year-100%USD 10.562023-08-25
5 year-100%USD 162.242021-08-25
Since inception-100%USD 893,952.572006-11-10

Yield10 Bioscience Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$810.00K

Net Income (TTM)

-$12.70M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Dec 16, 2024

YTEN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Yield10 Bioscience

Yield10 Bioscience, Inc. is an agricultural biotechnology firm focused on enhancing crop productivity through innovative solutions. The company utilizes its proprietary Trait Factory gene discovery platform to develop advanced oilseed varieties, particularly Camelina sativa, and collaborates with key industry players.

Products and Services
  • Development of enhanced oilseed varieties for agricultural applications
  • Proprietary Trait Factory gene discovery platform for genetic advancements
  • Licensing agreements with major industry partners like Bayer AG and J. R. Simplot
Growth Outlook
  • Recent partnerships with industry leaders indicate strong market interest
  • Focus on sustainable agricultural solutions aligns with global trends
  • Potential for increased revenue as product development progresses
Financial Highlights
  • Q2 2024 revenue of $450,000, up from $300,000 in Q1 2024
  • Operating expenses totaled $3.65 million in Q2 2024, reflecting ongoing R&D investments
  • Cash and cash equivalents of $733,000 as of June 30, 2024
Yield10 Bioscience, Inc. operates in the agricultural inputs sector, emphasizing biotechnology to improve crop yields. The company has made significant strides in developing its Trait Factory platform, which is crucial for identifying valuable genetic traits. Recent financial data shows a modest increase in revenue, indicating potential growth as the company continues to innovate and expand its product offerings. The partnerships with established industry players further enhance its market position, suggesting a promising outlook for future revenue generation. Despite current operating losses, the focus on research and development may lead to breakthroughs that could significantly impact the agricultural sector.
AI Generated • Aug 14, 2026

Industry

Biotechnology

Sector

Health Care

Employees

29

CEO

Oliver P. Peoples, PhD

Website

www.yield10bio.com

Headquarters

Woburn, MA 01801, US

YTEN Financials

Key Financial Metrics (TTM)

Gross Margin

-383.33%

Operating Margin

-24028.33%

Net Income Margin

-24091.67%

Return on Equity

-1508.09%

Return on Capital

-1996.81%

Return on Assets

-369.98%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$665.00K

Operating Income

-$12.59M

EBITDA

-$12.32M

Operating Cash Flow

-$5.80M

Capital Expenditure

-$19.00K

Free Cash Flow

-$5.82M

Cash & ST Invst.

$733.00K

Total Debt

$2.79M

Yield10 Bioscience Performance Analysis

Yield10 Bioscience annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 614,000N/A
20222022-12-31USD 450,000-26.7%
20232023-12-31USD 60,000-86.7%
Yield10 Bioscience sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-30N/A
Q42023-12-31N/A
Q12024-03-31400.0%
Q22024-06-3050.0%
Yield10 Bioscience annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -55.95N/A
20222022-12-31USD -66.2518.4%
20232023-12-31USD -43.66-34.1%
Yield10 Bioscience sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-3035.5%
Q42023-12-3134.3%
Q12024-03-3127.1%
Q22024-06-30-5.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

$450.00K

N/A

Gross Profit

$450.00K

+648.8%

Gross Margin

100.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

29

N/A

Net Income

-$3.24M

+12.0%

EBITDA

-$3.14M

+12.5%

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Total Cash

$733.00K

-68.6%

Total Debt

$2.79M

-20.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$1.09M

-61.4%

Short Term Debt

$1.70M

+148.0%

Return on Assets

-3.70%

N/A

Return on Invested Capital

15.05%

N/A

Free Cash Flow

-$574.00K

+81.5%

Operating Cash Flow

-$574.00K

+81.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KPLUYK+S AG
$9.60+1.91%
IPIIntrepid Potash, Inc.
$38.67+2.85%
BIOXBioceres Crop Solutions Corp.
$0.43+4.88%
VNPKFVerde AgriTech Ltd
$0.64-1.74%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About YTEN

What is the current price of Yield10 Bioscience?

Yield10 Bioscience is trading at N/A per share.

What is the 52-week range for Yield10 Bioscience?

Over the past 52 weeks, Yield10 Bioscience has traded between N/A and N/A.

How much debt does Yield10 Bioscience have?

As of the most recent reporting period, Yield10 Bioscience reported total debt of $3.18M.

How much cash does Yield10 Bioscience have on hand?

Yield10 Bioscience reported $1.07M in cash and cash equivalents in its most recent financial results.

What is Yield10 Bioscience’s dividend yield?

Yield10 Bioscience does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services